ONCS alert alert Breakout $0.21! Biotech ASCO 2013 stock. This stock has 3 phases II in course. Myelanoma, carcinoma (Merckell) and Lymphoma. Next results myelanoma phase II in ASCO 2013.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.